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Abstract 
The amount of software content within medical devices has grown considerably over 
recent years and will continue to do so as the level of complexity of medical devices 
increase. This is driven by the fact that software is introduced to produce 
sophisticated medical devices that would not be possible using only hardware. This 
therefore presents opportunities for software development SMEs to become medical 
device software development organisations. However, some obstacles need to be 
addressed and overcome in order to make the transition from being a generic 
software development organisation to becoming a medical device software 
development organisation. This paper describes these obstacles and how research 
that is currently being performed within the Regulated Software Research Group in 
Dundalk Institute of Technology may be used to assist with this transition.  
 
 
1.  Introduction - Background to Medical Device Software Development  
 
Today software is an increasingly important component of medical devices, as it 
enables often complex functional changes to be implemented without necessitating 
changes to the hardware [1]. As a consequence of the increasing demands for 
greater functionality within medical devices, the complexity of medical device 
software development also continues to increase [2]. This has resulted in increased 
demand for appropriate traceability and risk management processes and tools.  
 
It is very important that highly effective software development practices are in place 
within medical device companies due to the safety-critical nature of medical device 
software. In order to sell their products medical device companies must comply with 
the regulatory requirements of the countries in which they wish to market their 
devices [3]. Governments have established regulatory bodies to tackle these issues  
whose role is to define regulatory systems for medical devices and to ensure that 
only safe medical devices are placed on the market [4].  
 
While regulatory bodies offer some guidance on what software activities must be 
performed, no specific method for performing these activities is provided [5]. In this 
context in the United States (US), the Food and Drug Administration (FDA) Center 
for Devices and Radiological Health (CDRH) has published guidance papers which 
include risk-based activities to be performed during software validation [6], pre-
market submission [7] and when using off-the-shelf software in a medical device [8]. 
Although the CDRH guidance documents provide information on which software 
activities should be performed, they do not enforce any specific method for 
performing these activities. This can result in medical device software companies 
failing to comply with the expected requirements.  
 
To help address this situation a decision was taken by the medical device industry to 
recognize ISO/IEC 12207:1995 [9] (a general software engineering lifecycle process 
standard) as suitable for general medical device software development. 
Subsequently the Association for the Advancement of Medical Instrumentation 
(AAMI) software committee carefully reviewed ISO/IEC 12207:1995 and identified a 
number of shortcomings due to the fact that it was a generic standard. This resulted 
in the decision to create a new standard which was domain specific to medical 
device software development. The AAMI did not discard the work done with the 
ISO/IEC 12207:1995 and used it as the foundation for their new standard ―AAMI 
SW68, Medical device software – Software lifecycle processes‖ [10]. In 2006, a new 
standard IEC 62304 [11] was released that was based on the AAMI SW68 standard.  
 
The Council of the European Communities published in 1993 the Directive 
93/42/EEC (1993) [12],‖the Medical Device Directive‖ (MDD), on medical devices. 
The MDD is intended to ensure the safety of medical devices placed on the market 
in the European Union (EU), and has the backing of national legislation in member 
states. Amendments to this directive occurred via Directives 2000/70/EC (2000) [13], 
2001/104/EC (2001) [14], 2003/32/EC (2003) [15], and 2007/47/EC (2007) [16].  
 
Whenever we mention medical device guidelines within this paper we refer to the 
following medical device standards and guidelines: IEC 62304, FDA, the MDD, ISO 
14971 [17], EN 60601-4 [18], TIR 32 [19], IEC TR 80002-1[20], IEC 62366 
[21],GAMP 5 [22], IEC/TR 61508 [23], ISO 13485[24] and IEC 60812 [25].  
 
The remainder of this paper is structured as follows: Section 2 considers the reasons 
why software Small and Medium sized Enterprises (SMEs) are interested in 
becoming medical device SMEs and the challenges they face. In section 3 recent 
changes made by the EU and FDA regarding medical device software are 
discussed. Section 4 outlines the research currently being undertaken by the 
Regulated Software Research Group (RSRG) in Dundalk Institute of Technology 
which is of particular value to assist SMEs to develop medical device software.  
Section 5 discusses what initial steps can be taken by SMEs when embarking on 
medical device software development. A conclusion is provided in section 6 and 
future work is outlined.  
 
 
2. Why Software SMEs are Interested in Becoming Medical Device SMEs  
 
Software development SMEs are currently becoming medical device software 
development SMEs for two main reasons. The first of these is medical devices are 
becoming increasingly more complex and software facilitates increased functionality 
without the necessity to replace hardware. Therefore, due to growth in this area for 
this type of software there is an opportunity for software development SMEs to 
become medical device software development SMEs. The second reason is that 
software development SMEs currently developing health related software 
applications may now be actually developing medical device software. This is due to 
the most recent revision of the of Medical Device Directive [16], which states that 
standalone software may now be defined as a medical device.  
 
The challenge both types of organizations face is that to become a medical device 
software SME requires that software be developed in a regulatory compliant manner. 
This is essential as in order for a medical device to be marketed it is first necessary 
to achieve regulatory approval for the device in the region where it will be sold. This 
therefore means that such organizations need to become aware of what developing 
regulatory compliant software means and how they will have to change their current 
software development processes in order to fulfill this requirement. The starting point 
for such organizations is to become aware of the relevant regulations.  
 
 
 
3.  Changes Impacting Medical Device Software Development  
 
As medical devices are safety critical, they are subject to stringent regulations before 
they can be approved for use. Within the US medical devices must be approved by 
the FDA and likewise, medical devices for use within the EU must carry a CE 
conformance mark. This is awarded by notified bodies in each country. The most 
recent changes in the regulations, with regard to medical device software 
development, is the European MDD (2007/47/EC) [16] and the FDA Final Rule on 
Medical Device Data Systems [26]. 
  
On March 21st 2010, the MDD (2007/47/EC) came into force in the EU. This 
directive amends the MDD (93/42/EEC) [12], the Active Implantable Medical Device 
directive (90/385/EEC) [27] and the Biocides directive (98/8/EC) [28]. The most  
significant amendment within the MDD (2007/47/EC) is the provision for standalone 
software to be used as an active medical device. The MDD (2007/47/EC) Annex IX 
Section 1.4 states: ―stand-alone software is considered to be an active medical 
device‖. It defines an active medical device as ―any medical device operation which 
depends on a source of electrical energy or any source of power other than that 
generated by the human body or gravity‖[16].  
 
Consequently, standalone medical device software is now subject to regulation, 
independent of the hardware on which it resides. As software can now be seen as 
the only component of a medical device, improved guidance is needed in the 
development of this type of software to achieve regulatory compliance. While the 
MDD provides medical device manufacturers with a list of harmonized standards 
which can be used during development to aid in achieving regulatory compliance. 
However, no harmonized standards exist that can provide full guidance in the 
development of standalone software as an active medical device. The FDA does not 
provide software or standalone software specific regulations. They regulate medical 
devices and the elements that are included as part of that device, with software 
being regulated in this context. To help address this the FDA provide relevant 
guidance documents to assist with medical device software development [7], [6], [8].  
 
On April 18th 2011, the FDA Final Rule reclassifying Medical Device Data systems 
(MDDS) as Class I medical devices became effective [26]. MDDS’s are off-the-shelf 
or custom software or hardware products used alone, or in combination, that display 
unaltered medical device data or transfer, store or convert medical device data for 
future use, in accordance with a pre-set specification. Prior to the release of this final 
rule, MDDS were classified as Class III devices or as an accessory to the parent 
device, requiring the greatest amount of scrutiny before approval could be awarded.  
Whilst this ruling will make it simpler for companies developing MDDS software, it 
will also ring fence those which were previously beyond the net of regulatory 
requirements and make them subject to regulation. In addition, as part of this final 
rule a caveat was added to exclude devices that are used to actively monitor patients 
from being included as a MDDS. These devices remain classified as accessories 
and must undergo the same amount of regulatory conformance as the parent device 
to which they are connected [29]. Also standalone software such as Electronic 
Health Records (EHR) and Computerized Physician Order Entry (CPOE) fall outside 
of the scope of being defined as MDDS.  
 
 
4. Research to Help SMEs Develop Medical Device Software  
 
The RSRG was established in Dundalk Institute of Technology in February 2008. 
The research undertaken by the RSRG is focused on the development of an  
international Software Process Improvement (SPI) framework for the medical device 
industry. The objective of this framework is to provide a key enabler of best practice 
for the sector.  
The RSRG have undertaken a multi-faceted approach to establishing this framework 
including the examination of best practice from other safety-critical domains and 
determining how best practice SPI models can be successfully mapped onto 
regulatory frameworks. This has taken place through close cooperation with the 
medical device industry, relevant international standards bodies and the software 
process improvement community. A key element of this research is the use of 
empirical studies of industrial practice which has been utilized to inform theory. To 
undertake this work the RSRG have adopted a range of quantitative and qualitative 
research methodologies including experiments, quantitative analysis of data sets, 
case studies, action research and grounded theory to provide a rich analysis of the 
domain.  
 
The main focus of the RSRG is to support the growth of the medical device software 
industry within Ireland. However, this does not mean that their research has been 
restricted to Ireland, in fact the RSRG collaborates closely with international medical 
device organizations and SPI researchers. In particular, the RSRG is working as part 
of an international working group to revise the International Standard for Software 
Medical Device Software Lifecycle Processes (IEC 62304) and also closely with the 
Spice User Group to develop Medi SPICE [30]. Whilst the main deliverable for the 
RSRG is Medi SPICE they have also developed a number of lightweight assessment 
methods to assist software SMEs to become medical device software SMEs. The 
following subsections describe Medi SPICE and the lightweight assessment methods 
Med-Trace, Med-Adept and Medi SPICE-Adept.  
 
 
4.1  Medi SPICE  
Medi SPICE [30], [5] is a process assessment and improvement model which is 
domain specific to medical device software development and incorporates regulatory 
compliance. The results of a Medi SPICE assessment may be used to indicate the 
state of a medical device suppliers software practices in relation to the regulatory 
requirements of the industry, and identify areas for process improvement. The 
results of an assessment may also be used as a criterion for supplier selection.  
 
Medi SPICE is based on ISO/IEC 15504-5 [31] and provides coverage of the medical 
device software regulations. Like ISO/IEC 15504-5 and Automotive SPICE [32] it 
contains both a Process Reference Model (PRM) and Process Assessment Model 
(PAM) containing processes that provide comprehensive coverage of the FDA and  
European Council directives, and associated standards (e.g. ISO 14971, ISO 13485, 
IEC TR 80002-1, IEC 62304) for the complete software development lifecycle.  
 
The overall objective of Medi SPICE is to provide a conformity assessment scheme 
to support first, second or third party assessment results that may be recognized by 
the regulatory bodies. The PRM and PAM of the Medi SPICE assessment model is 
derived from relevant ISO/IEC 15504-5 processes as they are all applicable to the 
development of safety-critical medical device software. As the IEC 62304 standard 
contains the medical device software lifecycle processes that have to be adhered to 
in order to achieve medical device regulatory compliance, a key objective is to 
provide coverage of all processes that are either included in or referenced from IEC 
62304 and its associated standards.  
 
The Medi SPICE PRM and PAM is being released in phases and consists of a 
defined set of software processes that contain a comprehensive set of specific 
practices which when utilized assist medical device software development 
organizations to fulfill the regulatory guidelines and standards of the medical device 
industry. It also addresses the requirements for process assessment and can be 
utilized to facilitate process improvement.  
 
 
4.2  Med-Trace  
 
As traceability is central to the development of regulatory compliant software the 
RSRG decided to develop an assessment method specifically to assist companies to 
adhere to the traceability aspects of the medical device software standards. 
Emanating from the Adept method [33], previously developed by the authors, and 
based on CMMI® [34] and ISO/IEC 15504-5 software process reference models, 
Med-Trace is a lightweight assessment method that provides a means of assessing 
the capability of an organization in relation to medical device software traceability. 
Med-Trace enables software development organizations to gain an appreciation of 
the fundamental traceability best practices based on the software engineering 
traceability literature, software engineering process models (CMMI®, ISO/IEC 
15504-5), and the medical device software guidelines and standards. Med-Trace 
may be used to diagnose an organization’s weaknesses and strengths with relation 
to their medical device software development traceability practices.  
 
Med-Trace is composed of 8 stages. The assessment team typically consists of two 
assessors who conduct the assessment between them. Stage 1, involves a 
preliminary meeting between the assessment team and the company wishing to 
undertake a Med-Trace assessment. At stage 2, the lead assessor presents an 
overview of the Med-Trace assessment to members of the organization who will be 
involved in subsequent stages. Stage 3, provides a brief insight into project 
documentation. The first 3 stages are normally performed on the company’s 
premises, but the sample documentation collected in stage 3 is sometimes taken off- 
site as it can then be used to assist with the generation of additional questions for 
stage 4.  
 
During stage 4, the assessment team return onsite and key staff members from the 
organization are interviewed. A set of scripted questions are utilized as a basis for 
these interviews. These questions are based on the software traceability literature, 
traceability practices within the CMMI® and ISO/IEC 15504-5 models, and 
traceability practices that are required by the medical device industry. Additional 
questions may be asked based on the review of the documentation outlined in stage 
3.  
 
Stage 5, is a collaborative exercise between the assessors to develop the findings 
report using interview notes. Stage 6, involves presenting the findings report to 
participating staff in the organization. Stage 7, entails collaborating with staff to 
develop a pathway towards achieving highly effective and regulatory compliant 
traceability practices. The findings report provides guidance to the assessed 
company and focuses on practices that provide the greatest benefit in terms of the 
company’s business goals, in addition to their quality and compliance needs.  
At Stage 8, the assessed company is revisited approximately 3 months after the 
completion of stage 7 and their progress is reviewed against the recommended 
improvement path. The outcome of this stage is an updated improvement path and a 
final report detailing the progress that has been accomplished along with additional 
recommendations.  
 
 
4.3  Med-Adept  
 
The Adept method [33] was previously developed to provide a lightweight 
assessment of software processes from CMMI® and ISO/IEC 15504-5 and was not 
domain specific. The Adept method was then integrated with practices specified in 
medical device regulatory guidelines and standards to produce Med-Adept. Med-
Adept [35] is an assessment method that provides a means of assessing the 
software engineering capability for processes in relation to medical device software 
(both application and embedded software).  
 
Med-Adept enables software development organisations to gain an appreciation of 
the fundamental processes from CMMI®, ISO/IEC 15504-5 and IEC 62304 
(including additional practices required by other medical device guidelines and 
standards) through diagnosing strengths and weaknesses in their software 
development practices. Med-Adept was designed to adhere to 8 of the 10 criteria 
outlined by Anacleto et al. [36], for the development of lightweight assessment 
methods: low cost, detailed description of the assessment process, guidance for 
process selection, detailed definition of the assessment model, support for 
identification of risks and improvement suggestions, conformity with ISO/IEC 15504-
5, no specific software engineering knowledge required from companies’ 
representatives, and tool support is provided. The two exceptions to the criteria  
outlined by Anacleto et al. [36] are that no support is provided for high-level process 
modeling and only the authors currently have access to the method. Med-Adept also 
inherits the following requirements from Adept: improvement is more important than 
certification, a rating is not required, preparation time required by the company is 
minimised; assessment time is minimized, and companies should be enabled to 
select assessment in the process areas that are most relevant to their business 
goals.  
 
The main aims of Med-Adept are to either encourage non-medical device software 
development organisations to develop software for the medical device industry or to 
improve the software development processes within existing medical device software 
development organizations. However, the Med-Adept method also provides an ideal 
opportunity to educate software development organisations in terms of generic SPI. 
Therefore, the assessment would still have value even if the assessed software 
development company did not intend becoming a medical device software 
development company in the future. Consequently, Med-Adept provides medical 
device specific and non-medical device specific recommendations. Assessed 
companies are also supplied with feedback in relation to both CMMI® and ISO/IEC 
15504-5 which enables such companies to decide whether they wish to follow a 
CMMI® or an ISO/IEC 15504-5 improvement path. Med-Adept provides the 
assessed company with a findings document presented in terms of processes from 
CMMI®, ISO/IEC 15504-5 and practices required by medical device software 
standards and regulations (with a particular focus on IEC 62304).  
 
Med-Adept is composed of 8 stages which are similar to those in Adept and Med-
Trace. The assessment team consists of two assessors who conduct the 
assessment between them. Stage 1 involves a preliminary meeting between the 
assessment team and the software company wishing to undergo a software process 
assessment. The assessment team discuss the main drivers for the company 
embarking on a Med-Adept assessment and establish whether the company is 
interested in developing software for the medical device industry. During stage 2 the 
lead assessor provides an overview of Med-Adept for members of the assessed 
organisation who will be involved in subsequent stages. This session is used to 
remove any concerns that individuals may have.  
 
Stage 3 provides a brief review of project documentation. However, the primary 
source of data for Med-Adept is through a series of process interviews conducted 
during stage 4. In this stage key staff members from the assessed organisation are 
interviewed. There is an interview for each process. Each interview is scheduled to 
last approximately 1.5 hours. To enable stage 4 to be completed within 1 day the 
scope of a single Med-Adept assessment is restricted to 4 processes. Each interview 
involves two assessors and at least one representative from the company. Stage 5 is 
a collaborative exercise between the assessors to develop the findings report using 
interview notes for each of the assessed processes. The resultant findings report  
consists of a list of strengths, issues and suggested actions for each of the assessed 
processes.  
 
Stage 6, involves presenting the findings report to participating staff in the 
organisation. Stage 7, involves collaborating with staff to develop a roadmap. This 
provides guidance to the assessed company presenting practices that can provide 
the greatest benefit in terms of the company’s business goals. Companies wishing to 
develop software for the medical device industry are recommended to focus on 
establishing working practices that will assist them to fulfil the medical device 
regulations. Stage 8, involves revisiting the assessed company approximately 3 to 6 
months after the completion of stage 7 and reviewing progress against the SPI path. 
The outcome of this stage is an updated SPI path and a final report detailing the 
progress that has been accomplished along with additional recommendations. This 
stage provides feedback and assistance to the assessed company after a period of 
time and also assists in compiling research material in terms of SPI experiences. 
  
As Med-Adept is based on the Adept method, existing Adept questions were used as 
the foundation for the Med-Adept method. Questions were added to enable coverage 
of medical device regulations. Even though each assessment component adopts a 
CMMI® process area name, it also contains questions providing coverage of 
relevant ISO/IEC 15504-5 processes and medical device standards and regulations.  
 
Of the 12 Adept processes, 11 had medical device regulatory questions added for 
Med-Adept the exception being Measurement and Analysis which cannot be mapped 
against the processes of IEC 62304. Additionally, the existing Adept processes 
(which Med-Adept is founded on) did not provide coverage of 5 IEC 62304 
processes (Software Release, Software Maintenance, Software Problem Solution, 
Documentation, Software Safety Classification). Therefore, the current version of 
Med-Adept also does not provide coverage of these processes. Additionally, it 
should also be noted that the current release of Med-Adept does not include a Risk 
Management process.  
 
Therefore Med-Adept does not provide complete coverage of all the medical device 
regulations. However, the main aim of Med-Adept is not to provide comprehensive 
coverage of medical device regulations, but rather to assist organisations to improve 
their software practices and to encourage organizations to develop medical device 
software. To encourage the uptake of the Med-Adept assessment by software 
SMEs, on-site interviewing is restricted to one day thus minimizing the time and cost 
associated with the assessment.  
 
 
4.4  Medi SPICE-Adept  
The RSRG are currently developing a new assessment method (Medi SPICE-Adept) 
that will enable lightweight assessments to be performed against the Medi SPICE 
PAM. Medi SPICE-Adept follows the same structure as Med-Adept but with several 
key differences:  
 
•  Different processes then Med-Adept - Due to changes in the configuration of 
the processes that makeup Medi SPICE, Med Adept does not provide coverage of all 
Medi SPICE processes. Medi SPICE-Adept will provide coverage of all Medi SPICE 
processes but currently it consists of only 10 processes: Configuration Management, 
Change Request Management, Software Requirements Elicitation, Systems 
Requirements Analysis, Software Requirements Analysis, Software Construction, 
Software Integration, Software Testing, Verification, Validation  
 
 
•  Not based on CMMI® – Whereas, Med-Adept was founded on CMMI® 
questions, ISO/IEC 15504-5 and regulatory processes Medi SPICE-Adept is not 
based on CMMI® and does not include CMMI® questions. Medi SPICE-Adept is 
instead based on Medi SPICE processes.  
 
 
•  Includes agile and lean questions - Medi SPICE-Adept, unlike Med-Adept 
contains questions that refer to agile and lean practices. The output from an 
assessment is a set of strengths, issues and recommendations. As companies wish 
to increase the efficiency of their software development practices it was therefore 
considered essential to include agile and lean practices as part of the assessment. 
  
 
•  Reflects changes in latest directives’ and standards - Contains processes that 
are in-line with the latest changes in the MDD and the FDA rules. Med-Adept was 
initially developed to provide assessment of Medi SPICE processes that were 
aligned with ISO 12207:1995, however, both IEC 62304 and ISO/IEC 15504-5 are 
now being revised to align with ISO 12207:2008. It is therefore important that Medi 
SPICE is also revised to align with ISO 12207:2008. Therefore, Medi SPICE-Adept 
provides coverage of the revised Medi SPICE processes.  
 
 
•  May be performed over a number of days. Whereas a Med-Adept assessment 
typically involved only one day of on-site interviews, a Medi SPICE-Adept 
assessment currently consists of 2 days of on-site interviews and provides coverage 
of 10 process areas. However, in the future we plan to extend the scope of the 
assessment to include all 38 Medi SPICE processes and 10 subprocesses. 
Although, it will still be possible for the organization to be assessed in as few  
processes as they wish and in such cases the on-site interviews may be completed 
in one day.  
 
5.  What initial steps may be taken by SMEs  
 
The first step for a company is to discover if their software comes under the umbrella 
of a medical device as defined by either the revision of the European Council’s MDD 
or the FDA’s MDDS. The second step will then be to become aware of what 
standards need to be adhered to. This can be quite a time-consuming task for 
organizations as there are many different standards and it is difficult to determine the 
complete list of appropriate standards and the relationship between the different 
standards.  
 
The third step is for an organization to benchmark the state of their current software 
development processes against recommended best practices for medical device 
software development. In relation to this the author’s recommend adopting a Med-
Trace assessment to gain an understanding of how the traceability aspects of their 
software development processes could be improved to assist them to achieve 
regulatory compliance. Additionally, the author’s also recommend implementing a 
Medi SPICE-Adept assessment to gain an understanding as to the set of strengths 
and issues of an organization’s current software development processes in relation 
to developing regulatory compliant medical device software. The output from 
implementing both Med-Trace and Medi SPICE-Adept will be a set of 
recommendations that will provide a roadmap to put an organization on the correct 
path towards developing medical device software using compliant processes. It 
should be noted that if an organization decides to implement a Medi SPICE-Adept 
assessment this would remove the need to perform step 2 as this assessment is 
based on Medi SPICE which provides seamless alignment across all the required 
medical device software standards. It will then be important for the organization to 
prioritize the recommendations and start to implement them within their organization 
– this should be performed by implementing a few recommendations at a time as 
opposed to everything at once.  
 
After implementing the recommendations over a period of time the organization 
should then embark on another Medi SPICE-Adept and/or Med-Trace assessment to 
determine the level of improvement in relation to their software development 
processes. The output from this follow-up assessment will either be another set of 
recommendations or an indication that adequate processes are now in place for the 
organization to contact the national notified body for an official certification.  
 
 
6.  Conclusion  
 
The growing requirement for medical device software and the opportunities this 
provides for software SMEs continues to increase. The necessity for regulatory 
compliance and the lack of clear guidance are often cited as barriers to entry to this 
expanding market. Organizations that are currently developing medical device  
software are mainly focused on achieving regulatory compliance rather than also 
improving their development process and increasing their efficiency. For both of 
these situations the research undertaken by the RSRG is of particular value. Medi 
SPICE is a process assessment and improvement model which is domain specific to 
medical device software development. It has been developed to address the specific 
requirements of medical device software companies. Med-Trace and Medi SPICE-
Adept (based on Medi SPICE and Med-Adept) are lightweight assessment methods 
which provide effective mechanisms to assist software SMEs to enable them to put 
processes in place that will enable them to perform medical device software 
development. The RSRG plan to continue to build on its extensive experience and 
knowledge in this area. It is envisaged this will include the development of additional 
assessment methods and tools in the future as opportunities for innovation and 
improvement arise.  
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